Insight

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS 3 or more lesions

Fabio Zattoni/LinkedIn

Dec 27, 2024, 07:19

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS 3 or more lesions

A recent paper by Fabio Zattoni, Associate Professor at Urology Clinic, University of Padua, was mentioned by Juan Gómez Rivas, Associate Professor at The Complutense University of Madrid, on X:

“Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection.”

Authors: Fabio Zattoni, Giorgio Gandaglia, Roderick van den Bergh, Fabrizio Dal Moro, Giacomo Novara et al.

“Patients with a positive mpMRI (PI-RADS ≥3) but negative target and systematic biopsies still face risks of prostate cancer (26.8%) and clinically significant prostate cancer (19.3%). Follow-up strategies matter!

Best outcomes: repeat mpMRIs and biopsy based on clinical/radiological triggers (96% csPCA-free at 2 years).
Predictors: age, prostate volume, PI-RADS score, ASAP, and biopsy core count.

Tailored follow-up is essential for managing these high-risk cases.”

More posts featuring Juan Gómez Rivas.

cancer Fabio Zattoni Fabrizio Dal Moro Giacomo Novara Giorgio Gandaglia Juan Gómez Rivas OncoDaily Oncology PI-RADS prostate cancer Roderick van den Bergh

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care